A similar, tumor stage-related suppression of STING expression has been reported in malignant melanoma samples with the loss of STING expression in 23.2% of early malignant melanoma samples and 41.7% in more advanced, metastatic disease (Xia et al. 2016b). The gene discussed is STING1; the disease is melanoma.